Search

everythinglearnresearchcommunity

for

Search:↓

YH0618 granules may help prevent hair loss in breast cancer patients undergoing chemotherapy.

Hair transplant worked for a patient with a specific scalp condition after breast cancer chemotherapy.

Breast cancer survivors often face body image and sexual health issues, needing ongoing support and open communication with healthcare providers.

CK 5/6 expression in breast cancer is linked to negative hormone receptor status and higher tumor grade.

ROR-alpha may increase the growth of certain breast cancer cells by boosting aromatase, which could affect breast cancer prognosis.

Chemotherapy significantly lowers Inhibin A levels in breast cancer patients.

Long-term use of oral contraceptives, especially starting before age 20, may increase the risk of early-onset breast cancer.

Spironolactone is safe for breast cancer survivors with alopecia and does not increase cancer risk.

PLD is an effective and safer alternative for treating breast cancer.

Some breast cancer chemotherapy can cause permanent hair loss.

Some breast cancer patients still experience hair loss three years after chemotherapy, especially with taxane-based treatments.

Using finasteride or dutasteride does not increase the risk of male breast cancer.

Some breast cancer patients developed permanent hair loss after chemotherapy and hormonal therapy, showing patterns similar to common baldness and alopecia areata.

A woman's hair loss was initially mistaken for a common hair loss condition but was later found to be caused by breast cancer cells in her scalp.

Gemcitabine and paclitaxel are effective and safe as first-line treatment for metastatic breast cancer.

Local hormonal treatment for vulvovaginal atrophy is likely safe for women with estrogen receptor-positive breast cancer on aromatase inhibitors.

No definitive link between finasteride and male breast cancer, but further research is needed.

Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.

The document concludes that modern photo stories help represent and challenge how breast cancer affects women's identities and societal norms.

Finasteride use is not clearly linked to an increased risk of male breast cancer.

Some breast cancer patients on hormone therapy experience hair loss, and treatments like certain topical inhibitors and supplements may help without harming their cancer prognosis.

Some breast cancer treatments cause hair loss similar to male pattern baldness, which can be improved with minoxidil.

Taking 5-alpha reductase inhibitors does not increase the risk of breast cancer in men.

Patients with metastatic breast cancer treated with epirubicin and docetaxel had a good response and maintained their quality of life.

A breast cancer patient had lasting hair loss after chemotherapy, which improved with minoxidil treatment.

The number of advanced breast cancer cases in women under 40 has increased, but the overall numbers are still low.

Some breast cancer treatments, like taxanes, can cause long-term hair loss.

Oncoplastic breast surgery is more cost-effective than standard lumpectomy for large-breasted women despite being more expensive.

A man developed male breast cancer after four years of finasteride treatment for an enlarged prostate.

Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.